FHIT, EGFR, and MSH2

Possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in egyptian patients

Sheren F. Younes, Hayam A. Aiad, Nancy Y. Asaad, Mona A. Kandil, Yasodha Natkunam, Nadia M. Mokhtar

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

The high incidence and mortality of lung carcinoma in Egypt necessitates studying the factors that may be implicated in non-small cell lung carcinoma (NSCLC) pathogenesis and could affect patient management. The aim was to study FHIT, epidermal growth factor receptor (EGFR), and MSH2 protein expression in Egyptian patients with NSCLC. Immunohistochemical staining for FHIT, EGFR, and MSH2 was performed on 64 specimens from NSCLC patients and correlated with prognostic parameters, response to therapy, and overall survival. FHIT loss was observed in 64% of NSCLC patients and was significantly associated with SCC (P=0.003) and poor tumor grade (P=0.043). EGFR overexpression was observed in 47% of NSCLC patients and was significantly associated with SCC (P=0.002). MSH2 was reduced in 23.4% of NSCLC patients and was significantly associated with adenocarcinoma (P=0.024). In a univariate analysis, a significant relationship was seen between the poor overall survival in NSCLC patients and high T-stage (P=0.029), presence of metastasis (P=0.014), advanced-stage grouping (P=0.004), and FHIT loss (P=0.033). Further, FHIT loss was significantly related to disease progression in patients treated with chemotherapy (P=0.038). We conclude that all 3 markers play a role in the development of NSCLC in Egyptian patients. We suggest that FHIT loss be used as a predictor for progression in chemotherapy-treated NSCLC patients.

Original languageEnglish
Pages (from-to)275-283
Number of pages9
JournalApplied Immunohistochemistry and Molecular Morphology
Volume22
Issue number4
DOIs
Publication statusPublished - 1 Jan 2014

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Drug Therapy
Survival
Egypt
Disease Progression
Adenocarcinoma
Staining and Labeling
Neoplasm Metastasis
Carcinoma
Lung
Mortality
Incidence

Keywords

  • EGFR
  • FHIT
  • MSH2
  • non'small cell lung carcinoma

Cite this

Younes, Sheren F. ; Aiad, Hayam A. ; Asaad, Nancy Y. ; Kandil, Mona A. ; Natkunam, Yasodha ; Mokhtar, Nadia M. / FHIT, EGFR, and MSH2 : Possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in egyptian patients. In: Applied Immunohistochemistry and Molecular Morphology. 2014 ; Vol. 22, No. 4. pp. 275-283.
@article{4660cce0718b4ea2a8de595afbdcce43,
title = "FHIT, EGFR, and MSH2: Possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in egyptian patients",
abstract = "The high incidence and mortality of lung carcinoma in Egypt necessitates studying the factors that may be implicated in non-small cell lung carcinoma (NSCLC) pathogenesis and could affect patient management. The aim was to study FHIT, epidermal growth factor receptor (EGFR), and MSH2 protein expression in Egyptian patients with NSCLC. Immunohistochemical staining for FHIT, EGFR, and MSH2 was performed on 64 specimens from NSCLC patients and correlated with prognostic parameters, response to therapy, and overall survival. FHIT loss was observed in 64{\%} of NSCLC patients and was significantly associated with SCC (P=0.003) and poor tumor grade (P=0.043). EGFR overexpression was observed in 47{\%} of NSCLC patients and was significantly associated with SCC (P=0.002). MSH2 was reduced in 23.4{\%} of NSCLC patients and was significantly associated with adenocarcinoma (P=0.024). In a univariate analysis, a significant relationship was seen between the poor overall survival in NSCLC patients and high T-stage (P=0.029), presence of metastasis (P=0.014), advanced-stage grouping (P=0.004), and FHIT loss (P=0.033). Further, FHIT loss was significantly related to disease progression in patients treated with chemotherapy (P=0.038). We conclude that all 3 markers play a role in the development of NSCLC in Egyptian patients. We suggest that FHIT loss be used as a predictor for progression in chemotherapy-treated NSCLC patients.",
keywords = "EGFR, FHIT, MSH2, non'small cell lung carcinoma",
author = "Younes, {Sheren F.} and Aiad, {Hayam A.} and Asaad, {Nancy Y.} and Kandil, {Mona A.} and Yasodha Natkunam and Mokhtar, {Nadia M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/PAI.0b013e3182988fa5",
language = "English",
volume = "22",
pages = "275--283",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "4",

}

FHIT, EGFR, and MSH2 : Possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in egyptian patients. / Younes, Sheren F.; Aiad, Hayam A.; Asaad, Nancy Y.; Kandil, Mona A.; Natkunam, Yasodha; Mokhtar, Nadia M.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 22, No. 4, 01.01.2014, p. 275-283.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - FHIT, EGFR, and MSH2

T2 - Possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in egyptian patients

AU - Younes, Sheren F.

AU - Aiad, Hayam A.

AU - Asaad, Nancy Y.

AU - Kandil, Mona A.

AU - Natkunam, Yasodha

AU - Mokhtar, Nadia M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The high incidence and mortality of lung carcinoma in Egypt necessitates studying the factors that may be implicated in non-small cell lung carcinoma (NSCLC) pathogenesis and could affect patient management. The aim was to study FHIT, epidermal growth factor receptor (EGFR), and MSH2 protein expression in Egyptian patients with NSCLC. Immunohistochemical staining for FHIT, EGFR, and MSH2 was performed on 64 specimens from NSCLC patients and correlated with prognostic parameters, response to therapy, and overall survival. FHIT loss was observed in 64% of NSCLC patients and was significantly associated with SCC (P=0.003) and poor tumor grade (P=0.043). EGFR overexpression was observed in 47% of NSCLC patients and was significantly associated with SCC (P=0.002). MSH2 was reduced in 23.4% of NSCLC patients and was significantly associated with adenocarcinoma (P=0.024). In a univariate analysis, a significant relationship was seen between the poor overall survival in NSCLC patients and high T-stage (P=0.029), presence of metastasis (P=0.014), advanced-stage grouping (P=0.004), and FHIT loss (P=0.033). Further, FHIT loss was significantly related to disease progression in patients treated with chemotherapy (P=0.038). We conclude that all 3 markers play a role in the development of NSCLC in Egyptian patients. We suggest that FHIT loss be used as a predictor for progression in chemotherapy-treated NSCLC patients.

AB - The high incidence and mortality of lung carcinoma in Egypt necessitates studying the factors that may be implicated in non-small cell lung carcinoma (NSCLC) pathogenesis and could affect patient management. The aim was to study FHIT, epidermal growth factor receptor (EGFR), and MSH2 protein expression in Egyptian patients with NSCLC. Immunohistochemical staining for FHIT, EGFR, and MSH2 was performed on 64 specimens from NSCLC patients and correlated with prognostic parameters, response to therapy, and overall survival. FHIT loss was observed in 64% of NSCLC patients and was significantly associated with SCC (P=0.003) and poor tumor grade (P=0.043). EGFR overexpression was observed in 47% of NSCLC patients and was significantly associated with SCC (P=0.002). MSH2 was reduced in 23.4% of NSCLC patients and was significantly associated with adenocarcinoma (P=0.024). In a univariate analysis, a significant relationship was seen between the poor overall survival in NSCLC patients and high T-stage (P=0.029), presence of metastasis (P=0.014), advanced-stage grouping (P=0.004), and FHIT loss (P=0.033). Further, FHIT loss was significantly related to disease progression in patients treated with chemotherapy (P=0.038). We conclude that all 3 markers play a role in the development of NSCLC in Egyptian patients. We suggest that FHIT loss be used as a predictor for progression in chemotherapy-treated NSCLC patients.

KW - EGFR

KW - FHIT

KW - MSH2

KW - non'small cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84898540716&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e3182988fa5

DO - 10.1097/PAI.0b013e3182988fa5

M3 - Article

VL - 22

SP - 275

EP - 283

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 4

ER -